# Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

> **NCT06415708** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 134 (estimated)

## Conditions studied

- B Cell Lymphoma

## Interventions

- **DRUG:** Obinutuzumab Combined With Bendamustine

## Key facts

- **NCT ID:** NCT06415708
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415708, "Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06415708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*